SITC 2023 | Novel delivery of TLR7/8 agonists for treatment of metastatic solid tumors

Diwakar Davar, MD, University of Pittsburgh School of Medicine, Pittsburgh, PA, outlines the Phase I/II trial (NCT04799054) of the TransCon TLR7/8 agonist in squamous cell carcinoma with lymph nodes and subcutaneous tissues metastasis. The TransCon technology utilises a novel hydrogel delivery of the long-approved TLR7/8 agonist resiquimod, to overcome the problems posed by direct delivery of drugs to some of the metastatic environments. This mechanism of administration allows for sustained delivery of the drug to its tumor targets at a tolerable dosing schedule. TransCon TLR7/8 agonist’s efficacy is indicated by upregulation of TLR responses following delivery and the activation of both the innate and adaptive immune systems. There is clinical and pharmacodynamic evidence of tumor repression in both injected and non-injected tumors following delivery and increases in T cells and macrophages, suggesting a positive outlook on the future of this treatment. This interview took place at the Society for Immunotherapy of Cancer’s (SITC) 38th Annual Meeting in San Diego, CA.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.